| Citation: |
XIE Shu, SHAO Hua, LIU Bin, WANG Zhen. Effect observation of dronedarone in the treatment of patients with paroxysmal atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 89-92. DOI: 10.7619/jcmp.20223669
|
To observe the efficacy and safety of dronedarone in the treatment of patients with paroxysmal atrial fibrillation.
A total of 56 patients with paroxysmal atrial fibrillation were randomly divided into treatment group with 29 cases and control group with 27 cases. Patients in both groups were conducted with relevant assessments before enrollment, the contraindications to anticoagulation were also excluded, and then routine anticoagulation therapy was performed; the patients in the treatment group took dronedarone hydrochloride tablets orally for three consecutive months. Before and after treatment, number of times of atrial fibrillation attack, the maximum duration of a single atrial fibrillation attack, change of sinus resting heart rate, cardiac function indicators [left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVDd), left atrial diameter (LAD), N-terminal pro-B-type natriuretic peptide (NT-proBNP)]and adverse reactions were compared between two groups.
After treatment, the total number of times of atrial fibrillation attack and sinus resting heart rate in the treatment group decreased significantly when compared to those before treatment, and the longest duration of atrial fibrillation attack shortened significantly (P < 0.05); after treatment, the total number of times of atrial fibrillation attack and sinus resting heart rate in the treatment group were significantly lower than those in the control group, and the longest duration of atrial fibrillation attack was significantly shorter than that in the control group (P < 0.05). After treatment, LVEF in the treatment group increased significantly when compared to that before treatment, while LVDd, LAD and NT-proBNP decreased significantly when compared to those before treatment (P < 0.05); after treatment, LVEF in the treatment group was significantly higher than that in the control group, while LVDd, LAD and NT-proBNP were significantly lower than those in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the control group was 7.41%, which showed no significant difference when compared to 6.90% in the treatment group (P>0.05).
Dronedarone can effectively control the ventricular rate of patients with paroxysmal atrial fibrillation, shorten the duration of atrial fibrillation attack, reduce the frequency of atrial fibrillation attack, maintain sinus rhythm, improve cardiac function indicators, and cause less adverse reactions.
| [1] |
SUN X R, HE S N, LIN Z Y, et al. Radiofrequency catheter ablation versus cryoballoon ablation in the treatment of paroxysmal atrial fibrillation: a cost-effectiveness analysis in China[J]. Clin Ther, 2019, 41(1): 78-91. doi: 10.1016/j.clinthera.2018.11.008
|
| [2] |
SBAROUNI E, KOGERAKIS N, STAVRIDIS G. 68-year-old woman with paroxysmal atrial fibrillation[J]. Heart, 2018: heartjnl-2018.
|
| [3] |
SOGA F, TANAKA H, MOCHIZUKI Y, et al. Combined assessment of left atrial volume parameters for predicting recurrence of atrial fibrillation following pulmonary vein isolation in patients with paroxysmal atrial fibrillation[J]. Echocardiography, 2019, 36(5): 862-869. doi: 10.1111/echo.14315
|
| [4] |
KRANERT M, SHCHETYNSKA-MARINOVA T, LIEBE V, et al. Recurrence of atrial fibrillation in dependence of left atrial volume index[J]. Vivo, 2020, 34(2): 889-896. doi: 10.21873/invivo.11854
|
| [5] |
MOHANTY S, DELLA ROCCA D G, GIANNI C, et al. Predictors of recurrent atrial fibrillation following catheter ablation[J]. Expert Rev Cardiovasc Ther, 2021, 19(3): 237-246. doi: 10.1080/14779072.2021.1892490
|
| [6] |
BODDUM K, SALJIC A, JESPERSEN T, et al. A novel SCN5A variant associated with abnormal repolarization, atrial fibrillation, and reversible cardiomyopathy[J]. Cardiology, 2018, 140(1): 8-13. doi: 10.1159/000487475
|
| [7] |
NATTEL S, GUASCH E, SAVELIEVA I, et al. Early management of atrial fibrillation to prevent cardiovascular complications[J]. Eur Heart J, 2014, 35(22): 1448-1456. doi: 10.1093/eurheartj/ehu028
|
| [8] |
VLACHOS K, LETSAS K P, KORANTZOPOULOS P, et al. Prediction of atrial fibrillation development and progression: current perspectives[J]. World J Cardiol, 2016, 8(3): 267. doi: 10.4330/wjc.v8.i3.267
|
| [9] |
JASON G, ANDRADE, MD C, et al. The 2020 Canadian cardiovascular society/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation[J]. Can J Cardiol, 2020, 36(12): 1847-1948. doi: 10.1016/j.cjca.2020.09.001
|
| [10] |
NATTEL S, DOBREV D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation[J]. Nat Rev Cardiol, 2016, 13(10): 575-590. doi: 10.1038/nrcardio.2016.118
|
| [11] |
JANUARY C T, WANN L S, CALKINS H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society[J]. Circulation, 2019, 140(6): e125-e151.
|
| [12] |
HEIJMAN J, HOHNLOSER S H, CAMM A J. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future[J]. Europace, 2021, 23(Supplement_2): ii14-ii22. doi: 10.1093/europace/euaa426
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: